Abstract:Methotrexate (MTX)-induced myelopathy is a rare but serious adverse effect of intrathecal (IT) MTX, which may mimic subacute combined degeneration (SCD). MTX disrupts the normal synthesis of methionine, which plays an important role in maintaining myelin sheath integrity, resulting in degeneration of the dorsal columns. This degeneration does not respond to classic treatment with vitamin B12 and folate supplementation, unlike SCD. Here, we describe a case of a 45-year-old woman with Philadelphia-positive B-cell acute lymphoblastic leukemia treated with hyperCVAD regimen with ponatinib, who after 14 doses of prophylactic IT MTX, developed progressive lower extremity weakness, paresthesias, gait instability, saddle anesthesia, and bowel/bladder dysfunction. Her neurologic exam was also notable for diffuse hyporeflexia. The onset of symptoms followed a diarrheal infection, and an initial MRI spine showed no evidence of abnormal enhancement. She was initially treated with intravenous immunoglobulins for presumed acute inflammatory demyelinating polyneuropathy. She then re-presented one week later with progressively worsening symptoms. A repeat MRI spine revealed a new longitudinally extensive T2 hyperintense signal within the dorsal columns from T7 to T12. CSF results were notable for mild pleocytosis and increased myelin basic protein; the latter of which is often seen in MTX-induced myelopathy. The patient received high-dose administration of key metabolites of the methyl-transfer pathway including S-adenosylmethionine (PO 400mg three times daily), folinate (IV 20mg four times daily), cyanocobalamin (PO 1000mcg once daily) and methionine (PO 5mg once daily) for 7 days. This treatment regimen resulted in both clinical and radiographic improvement. Subsequent MRI spine demonstrated complete resolution of the abnormal signal in the thoracic cord. This case highlights (1) the diagnostic complexity of IT MTX-induced myelopathy (2) the role response to treatment plays in uncovering this diagnosis, and (3) how the replacement of folate metabolites facilitates both radiographic and clinical improvement in IT MTX-induced myelopathy.

A case of myelopathy due to intrathecal chemotherapy and literature review

Multiple Myeloma with Isolated Central Nervous System Relapse after Autologous Stem Cell Transplantation: A Case Report and Review of the Literature

Clinical research on acute paraplegia resulting from intrathecal chemotherapy

Clinical and Neuroimaging Characteristics and Prognosis of Patients with Hepatic Myelopathy and Hepatic Encephalopathy

Psychosocial interventions in the management of recurrent headache disorders. 3: Policy considerations for implementation.

Isolated primary non-hodgkin's lymphoma of the thoracic spine: A case report with a review of the literature

Myelopathy following intrathecal methotrexate administration:Review of English literature

Dorsal column myelopathy after intrathecal chemotherapy for leukemia

[Severe adult mucoviscidosis with protein diarrhea].

Myelopathies Due to Structural Cervical and Thoracic Disease

Developmental and genetic determinants of leadership role occupancy among women.

Paraplegia resulting from intrathecal methotrexate administration in 11 cases:Review of Chinese literature

Pathophysiology of obsessive-compulsive disorder.

Pathophysiology of cervical myelopathy (Review)

Symptomatic Treatment of Myelopathy

Intramedullary schwannoma of conus medullaris with syringomyelia: a case report and literature review

Anterior lumbosacral polyradiculopathy after intrathecal administration of methotrexate

Myelopathy Associated with Systemic Lupus Erythematosus: a Clinical Analysis of 10 Cases and Review of Literature

Intraspinal nerve sheath myxoma : a case report and review of literature

Ncmp-05. Clinical And Radiographic Improvement With Replacement Of Folate Metabolites In A Patient With Intrathecal Methotrexate-Induced Myelopathy

[A Case of Peripheral T Cell Lymphomas-Unspecified in Vertebra Canal].